Evidence for vaccine synergy between Borrelia burgdorferi decorin binding protein A and outer surface protein A in the mouse model of lyme borreliosis.
Mice immunized with either the predominantly vector-stage lipoprotein outer surface protein A (OspA) or the in vivo-expressed lipoprotein decorin binding protein A (DbpA) are protected against Borrelia burgdorferi challenge. DbpA-OspA combinations protected against 100-fold-higher challenge doses than did either single-antigen vaccine and conferred significant protection against heterologous B. burgdorferi, B. garinii, and B. afzelii isolates, suggesting that there is synergy between these two immunogens.
Hanson
M S
MS
MedImmune, Inc., Gaithersburg, Maryland 20878, USA.
Patel
N K
NK
Cassatt
D R
DR
Ulbrandt
N D
ND
D018829:Adhesins, Bacterial; D000818:Animals; D000954:Antigens, Surface / Q000276:immunology*; D001425:Bacterial Outer Membrane Proteins / Q000276:immunology*; D001426:Bacterial Proteins; D001428:Bacterial Vaccines; D002352:Carrier Proteins / Q000276:immunology*; D004195:Disease Models, Animal; D005260:Female; D008074:Lipoproteins; D008193:Lyme Disease / Q000517:prevention & control*; D022123:Lyme Disease Vaccines / Q000276:immunology*; D051379:Mice; D008809:Mice, Inbred C3H; D017778:Vaccines, Combined / Q000276:immunology
D018829:Adhesins, Bacterial; D000954:Antigens, Surface; D001425:Bacterial Outer Membrane Proteins; D001426:Bacterial Proteins; D001428:Bacterial Vaccines; D002352:Carrier Proteins; C112557:DdpB protein, Borrelia burgdorferi; D008074:Lipoproteins; D022123:Lyme Disease Vaccines; C072045:OspA protein; D017778:Vaccines, Combined